Danske Bank’s Myriad Genetics MYGN Stock Holding History

Danske Bank’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-108,641	Closed	-$1.49M	–	1425
2024 Q4	$1.49M	Buy	+108,641	New	+$2M	﹤0.01%	775

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Danske Bank's MYGN Position: Q1 2025 in Review

Danske Bank sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 108,641 shares — an estimated $1.49M sold.

Danske Bank first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $1.49M in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Danske Bank reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Danske Bank sold 108,641 Myriad Genetics shares in Q1 2025, an estimated $1.49M.
Danske Bank first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
Danske Bank's Myriad Genetics position peaked at $1.49M in Q4 2024.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Danske Bank's 13F filing for Q1 2025, filed 18 Dec 2025.